These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29077146)

  • 21. Prognostic impact of intensive statin therapy on N-terminal pro-BNP level in non-ST-segment elevation acute myocardial infarction patients.
    Shehata M; Samir A; Dardiri M
    J Interv Cardiol; 2017 Dec; 30(6):514-521. PubMed ID: 28812321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of β-blockers on left ventricular remodeling in patients with preserved ejection fraction after acute myocardial infarction.
    Horiuchi Y; Tanimoto S; Aoki J; Nakajima H; Hara K; Tanabe K
    Int J Cardiol; 2016 Oct; 221():765-9. PubMed ID: 27428318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Administration of a loading dose of atorvastatin before percutaneous coronary intervention prevents inflammation and reduces myocardial injury in STEMI patients: a randomized clinical study.
    Liu HL; Yang Y; Yang SL; Luo JP; Li H; Jing LM; Shen ZQ
    Clin Ther; 2013 Mar; 35(3):261-72. PubMed ID: 23410871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of high-dose rosuvastatin preloading in patients undergoing percutaneous coronary intervention: a meta-analysis of fourteen randomized controlled trials.
    Pan Y; Tan Y; Li B; Li X
    Lipids Health Dis; 2015 Aug; 14():97. PubMed ID: 26306625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME].
    Ovrakh T; Serik S; Kochubiei O
    Georgian Med News; 2017 Apr; (265):7-14. PubMed ID: 28574378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-oxidative stress effect of loading-dose rosuvastatin prior to percutaneous coronary intervention in patients with acute coronary syndrome: a prospective randomized controlled clinical trial.
    Liang D; Zhang Q; Yang H; Zhang R; Yan W; Gao H; Wang J; Zhang X; Chen Y; Cao F
    Clin Drug Investig; 2014 Nov; 34(11):773-81. PubMed ID: 25186834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Dapagliflozin on Ventricular Remodeling and Prognosis in Patients with Coronary Atherosclerotic Heart Disease Undergoing Percutaneous Coronary Intervention.
    Ye L; Wang K; Sheng H; Shi X; Yan L
    Altern Ther Health Med; 2024 Apr; 30(4):204-208. PubMed ID: 37944964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rationale and design of RETAIN study: Rosuvastatin Effect on Telomere-telomerase system in Acute coronary syndrome patients undergoing percutaneous coronary Intervention.
    Zhuang XD; Liao LZ; Guo Y; Li Y; Liao XX; Hu X; Du ZM
    Int J Cardiol; 2015 Apr; 184():388-390. PubMed ID: 25745990
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment outcomes and therapeutic evaluations of patients with left ventricular aneurysm.
    Sui Y; Teng S; Qian J; Zhao Z; Zhang Q; Wu Y
    J Int Med Res; 2019 Jan; 47(1):244-251. PubMed ID: 30270805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
    Yun KH; Shin SN; Ko JS; Rhee SJ; Kim NH; Oh SK; Jeong JW
    J Cardiol; 2012 Nov; 60(5):383-8. PubMed ID: 22884684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
    Krum H; Ashton E; Reid C; Kalff V; Rogers J; Amarena J; Singh B; Tonkin A
    J Card Fail; 2007 Feb; 13(1):1-7. PubMed ID: 17338996
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Significance of Cys-C and hs-CRP in Coronary Heart Disease Patients Undergoing Percutaneous Coronary Intervention.
    Tan Z; Li L; Ma Y; Geng X
    Braz J Cardiovasc Surg; 2019; 34(1):17-21. PubMed ID: 30810669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention].
    Jiang FY; Sun LP; Yang J
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Dec; 31(12):1607-10. PubMed ID: 22384544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of cardiac resynchronization therapy on disease progression in patients with congestive heart failure.
    Bonanno C; Ometto R; Pasinato S; Finocchi G; La Vecchia L; Fontanelli A
    Ital Heart J; 2004 May; 5(5):364-70. PubMed ID: 15185900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of high flow hemodialysis on the biomarker of myocardium injury and the cardiac function related records in uremia patients].
    Tang L; Deng X; Dai Q; Xiao H; Shu Y; Jiang M; Wei L; Wang L
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2017 Jun; 29(6):547-550. PubMed ID: 28625246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-existing treatment with aspirin or statins influences clinical presentation, infarct size and inflammation in patients with de novo acute coronary syndromes.
    Weidmann L; Obeid S; Mach F; Shahin M; Yousif N; Denegri A; Muller O; Räber L; Matter CM; Lüscher TF
    Int J Cardiol; 2019 Jan; 275():171-178. PubMed ID: 30344063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study: study protocol for a randomized controlled trial.
    Fonseca FAH; Izar MC; Maugeri IML; Berwanger O; Damiani LP; Pinto IM; Szarf G; França CN; Bianco HT; Moreira FT; Caixeta A; Alves CMR; Soriano Lopes A; Klassen A; Tavares MFM; Fonseca HA; Carvalho ACC;
    Trials; 2017 Dec; 18(1):601. PubMed ID: 29258572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of usefulness of N-terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Haeck JD; Verouden NJ; Kuijt WJ; Koch KT; Van Straalen JP; Fischer J; Groenink M; Bilodeau L; Tijssen JG; Krucoff MW; De Winter RJ
    Am J Cardiol; 2010 Apr; 105(8):1065-9. PubMed ID: 20381654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of NT-proBNP, 3D LA volume and LV dyssynchrony in patients with acute STEMI undergoing primary percutaneous intervention.
    Siva Sankara C; Rajasekhar D; Vanajakshamma V; Praveen Kumar BS; Vamsidhar A
    Indian Heart J; 2015; 67(4):318-27. PubMed ID: 26304563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protection of Ivabradine Combined with Trimetazidine on Myocardial Injury after Percutaneous Coronary Intervention in Patients with Coronary Artery Disease Evaluated by Magnetic Resonance Image under Convolutional Neural Network.
    Chen C
    Contrast Media Mol Imaging; 2021; 2021():3150938. PubMed ID: 34629991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.